COMBINATION CANCER THERAPIES
The disclosure provides methods of treatment for cancer in patients using bispecific anti-IGF-1R, anti-ErbB3 antibodies in combination with one or more therapeutic agents that impede regulatory T-cell agents. In certain embodiments, said one or more therapeutic agent may be an antagonistic anti-rece...
Gespeichert in:
Hauptverfasser: | , , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The disclosure provides methods of treatment for cancer in patients using bispecific anti-IGF-1R, anti-ErbB3 antibodies in combination with one or more therapeutic agents that impede regulatory T-cell agents. In certain embodiments, said one or more therapeutic agent may be an antagonistic anti-receptor antibody that immunospecifically binds human PD-L1. |
---|